Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSPNASDAQ:IRTCNASDAQ:LQDANASDAQ:NARI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$152.66+2.0%$155.46$123.00▼$225.00$4.50B1.39561,510 shs390,694 shsIRTCiRhythm Technologies$141.000.0%$110.66$55.92▼$142.68$4.50B1.34472,748 shs664,244 shsLQDALiquidia$18.88-2.2%$14.56$8.26▼$19.41$1.61B0.241.02 million shs1.08 million shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.32 million shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems0.00%+0.71%+1.49%-17.36%-4.43%IRTCiRhythm Technologies0.00%+2.40%+39.66%+25.77%+40.17%LQDALiquidia0.00%+23.24%+37.61%+16.54%+53.62%NARIInari Medical0.00%0.00%0.00%+0.05%+70.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINSPInspire Medical Systems4.7097 of 5 stars4.41.00.04.82.52.51.9IRTCiRhythm Technologies1.3253 of 5 stars2.52.00.00.03.60.00.6LQDALiquidia2.651 of 5 stars3.60.00.00.03.14.20.6NARIInari Medical0.4543 of 5 stars1.10.00.00.01.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.73Moderate Buy$211.9138.81% UpsideIRTCiRhythm Technologies 2.91Moderate Buy$128.55-8.83% DownsideLQDALiquidia 3.11Buy$27.1343.67% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideCurrent Analyst Ratings BreakdownLatest LQDA, NARI, INSP, and IRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/12/2025LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/9/2025LQDALiquidiaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$27.00 ➝ $29.005/6/2025INSPInspire Medical SystemsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$220.00 ➝ $200.005/6/2025INSPInspire Medical SystemsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$235.00 ➝ $195.005/6/2025INSPInspire Medical SystemsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$195.00 ➝ $174.005/6/2025INSPInspire Medical SystemsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$230.00 ➝ $236.005/5/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/5/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$34.00 ➝ $36.005/2/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$152.00 ➝ $139.005/2/2025IRTCiRhythm TechnologiesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$133.00 ➝ $150.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$840.11M5.36$1.46 per share104.41$23.25 per share6.57IRTCiRhythm Technologies$618.59M7.28N/AN/A$6.85 per share20.58LQDALiquidia$14.14M114.11N/AN/A$0.73 per share25.86NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$53.51M$2.1788.2447.412.866.67%8.19%7.09%8/5/2025 (Estimated)IRTCiRhythm Technologies-$123.41M-$3.14N/AN/AN/A-19.14%-118.83%-11.34%N/ALQDALiquidia-$78.50M-$1.58N/AN/AN/A-765.38%-163.21%-67.14%N/ANARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ALatest LQDA, NARI, INSP, and IRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LQDALiquidia-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 million3/19/2025Q4 2024LQDALiquidia-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 million2/20/2025Q4 2024IRTCiRhythm Technologies-$0.29$0.01+$0.30-$0.04$158.30 million$164.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A7.136.22IRTCiRhythm Technologies9.006.276.12LQDALiquidiaN/A6.336.33NARIInari MedicalN/A1.771.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%IRTCiRhythm TechnologiesN/ALQDALiquidia64.54%NARIInari Medical90.98%Insider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems2.30%IRTCiRhythm Technologies1.10%LQDALiquidia30.10%NARIInari Medical10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems76029.49 million28.45 millionOptionableIRTCiRhythm Technologies1,79031.93 million31.09 millionOptionableLQDALiquidia5085.49 million59.16 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableLQDA, NARI, INSP, and IRTC HeadlinesRecent News About These CompaniesThe top nitinol cardiac medtech news of 2025 (so far)May 13, 2025 | medicaldesignandoutsourcing.comStryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPSMay 2, 2025 | msn.comExpert Testimony Supporting POPR Can Be An Effective StrategyApril 21, 2025 | jdsupra.comVolta Medical Appoints Bill Hoffman as Executive Chairman of the Board of DirectorsApril 8, 2025 | finance.yahoo.com8 spine, orthopedic acquisitions in Q1March 27, 2025 | beckersspine.comOkami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery CatheterMarch 26, 2025 | finance.yahoo.comHow Is Inari Medical Inc. (NASDAQ:NARI) Positioned in the Medical Devices Sector?March 25, 2025 | kalkinemedia.comIf You Could Only Hold 3 Investments for Life, Consider These (NARI)March 10, 2025 | marketbeat.comStryker’s Inari Medical Launches Artix Thrombectomy SystemMarch 7, 2025 | evtoday.comStryker’s Inari Medical launches Artex thrombectomy systemMarch 7, 2025 | massdevice.comInari Medical introduces thrombectomy system for arterial thrombus casesMarch 7, 2025 | msn.comInari Medical acquisition could provide Stryker with foothold in peripheral vascular marketFebruary 28, 2025 | expresshealthcare.inWearable defibrillator maker Kestra Medical plots $150M IPOFebruary 26, 2025 | fiercebiotech.comStryker grows cardiovascular division with Inari Medical acquisitionFebruary 24, 2025 | medicaldevice-network.comStryker Completes Acquisition of InariFebruary 20, 2025 | evtoday.comStryker concludes Inari Medical acquisition for $4.9bnFebruary 20, 2025 | finance.yahoo.comStryker completes Inari Medical acquisitionFebruary 20, 2025 | beckersspine.comInari Medical, Inc. (NARI): the Best Performing Healthcare Stock So Far in 2025February 20, 2025 | msn.comStryker completes acquisition of Inari MedicalFebruary 19, 2025 | massdevice.comStryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segmentFebruary 19, 2025 | globenewswire.comStryker in the headlines: 6 updates to knowFebruary 14, 2025 | beckersspine.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumThe Most Inspiring Small Businesses of 2025 [Survey]By MarketBeat Staff | May 1, 2025View The Most Inspiring Small Businesses of 2025 [Survey]These 3 Rock Star Entertainment Stocks Are Dominating 2025By Leo Miller | May 7, 2025View These 3 Rock Star Entertainment Stocks Are Dominating 2025Survey: America’s Most Inspirational Women Business Leaders [2025]By MarketBeat Staff | May 7, 2025View Survey: America’s Most Inspirational Women Business Leaders [2025]LQDA, NARI, INSP, and IRTC Company DescriptionsInspire Medical Systems NYSE:INSP$152.66 +2.97 (+1.98%) Closing price 05/16/2025 03:59 PM EasternExtended Trading$156.29 +3.63 (+2.38%) As of 05/16/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.iRhythm Technologies NASDAQ:IRTC$141.00 -0.04 (-0.03%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$136.06 -4.94 (-3.50%) As of 05/16/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Liquidia NASDAQ:LQDA$18.88 -0.42 (-2.18%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$18.68 -0.20 (-1.05%) As of 05/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
